- Home
- SONM vs NERV Comparison
SONM vs NERV Comparison
Compare SONM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONM | NERV |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 269.6M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SONM | NERV |
|---|---|---|
| Price | $3.20 | $6.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 18.8K | ★ 320.5K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,298,000.00 | $41,175,600.00 |
| Revenue This Year | $127.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $1.15 |
| 52 Week High | $12.30 | $12.46 |
Technical Indicators
Market Signals| Indicator | SONM | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 45.30 |
| Support Level | $0.64 | $5.34 |
| Resistance Level | $7.08 | $6.69 |
| Average True Range (ATR) | 0.50 | 0.70 |
| MACD | -0.09 | -0.25 |
| Stochastic Oscillator | 41.46 | 18.24 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc operates a digital asset management platform.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.